




Suggested Formula	Atropine Sulfate 1% Ophthalmic Ointment (Emulsion, 4 g)	FIN	F 001 769
-------------------	---	-----	-----------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Atropine Sulfate 40% Stock Solution †	0.10	mL				
Chlorobutanol 1% Stock Solution ††	1.6	mL				
Lanolin (Anhydrous), USP	0.40	g				
Petrolatum (White), USP	2.14	g				
† Atropine Sulfate 40% Stock Solution						
Atropine Sulfate, USP	0.100	g				
Sterile Water for Injection, USP	0.15	mL				
Sterile Water for Injection, USP	q.s. to 0.25	mL				
†† Chlorobutanol 1% Stock Solution						
Chlorobutanol (Anhydrous), NF	0.10	g				
Mineral Oil (Light), NF	10.0	mL				



DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. THE PHARMACIST IS ADVISED THAT THE SUGGESTED FORMULA IS PRESENTED AT A SPECIFIED STRENGTH AND QUANTITY, AND THAT ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. FURTHER, THE FORMULA SHOULD ONLY BE PROVIDED UPON THE REQUEST AND AUTHORIZATION OF A LICENSED PRESCRIBER. PHARMACISTS USING THIS SUGGESTED FORMULA ARE ADVISED THAT ITS USE AS A MEANS OF THERAPEUTIC INTERVENTION IS BASED ON THE PRESCRIBER'S INDEPENDENT CLINICAL JUDGEMENT AND THE PROFESSIONAL EXPERTISE OF THE PHARMACIST. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE PRECISE STABILITY OF THIS SUGGESTED FORMULA. NO CLAIMS ARE BEING MADE AS TO THE SAFETY OR CLINICAL EFFICACY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. FURTHERMORE, THE NETWORK, TAKES NO RESPONSIBILITY AND MAKES NO RECOMMENDATIONS IN DISPENSING THIS PRODUCT. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.



Suggested Formula	Atropine Sulfate 1% Ophthalmic Ointment (Emulsion, 4 g)	FIN	F 001 769
-------------------	---	-----	-----------

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Light sensitive (protect from light whenever possible):

Atropine Sulfate, Lanolin (Anhydrous), Petrolatum (White), Mineral Oil (Light)

Air Sensitive (protect from air whenever possible):

Atropine Sulfate

Suggested Preparatory Guidelines

Non-Sterile Preparation Sterile Preparation

Processing Error /

Testing Considerations:

To account for processing error, sterility and endotoxin testing considerations during preparation, it is suggested to measure an additional **30 to 40%** of the required quantities of ingredients.

Special Instruction:

This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within *USP 797*. Only trained and qualified personnel must prepare this formula.

All heat stable, reusable materials and equipment must be sterilized and depyrogenated by dry heat sterilization at 250°C for 2 hours prior to use.

Every batch of final product compounded using this procedure must be sterility and endotoxin tested before being dispensed.

Protective apparel, such as a sterile gown, sterile gloves, shoe covers, head cap, eyewear and face-masks should always be worn. In addition, proper personnel cleansing must be done before entering the buffer or clean area.

Filter integrity must be validated by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. THE PHARMACIST IS ADVISED THAT THE SUGGESTED FORMULA IS PRESENTED AT A SPECIFIED STRENGTH AND QUANTITY, AND THAT ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. FURTHER, THE FORMULA SHOULD ONLY BE PROVIDED UPON THE REQUEST AND AUTHORIZATION OF A LICENSED PRESCRIBER. PHARMACISTS USING THIS SUGGESTED FORMULA ARE ADVISED THAT ITS USE AS A MEANS OF THERAPEUTIC INTERVENTION IS BASED ON THE PRESCRIBER'S INDEPENDENT CLINICAL JUDGEMENT AND THE PROFESSIONAL EXPERTISE OF THE PHARMACIST. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE PRECISE STABILITY OF THIS SUGGESTED FORMULA. NO CLAIMS ARE BEING MADE AS TO THE SAFETY OR CLINICAL EFFICACY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. FURTHERMORE, THE NETWORK, TAKES NO RESPONSIBILITY AND MAKES NO RECOMMENDATIONS IN DISPENSING THIS PRODUCT. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.



Suggested Formula	Atropine Sulfate 1% Ophthalmic Ointment (Emulsion, 4 g)	FIN	F 001 769
-------------------	---	-----	-----------

SUGGESTED PREPARATION (for 4 g)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): ____	Processing Error	Qty. to measure
Atropine Sulfate 40% Stock Solution § †	0.10	mL			
Chlorobutanol 1% Stock Solution § ††	1.6	mL			
Lanolin (Anhydrous), USP §	0.40	g			
Petrolatum (White), USP §	2.14	g			
† Atropine Sulfate 40% Stock Solution					
Atropine Sulfate, USP §	0.100	g	---	---	
Sterile Water for Injection, USP §	0.15	mL	---	---	
Sterile Water for Injection, USP §	q.s. to 0.25	mL	---	---	
†† Chlorobutanol 1% Stock Solution					
Chlorobutanol (Anhydrous), NF §	0.10	g	---	---	
Mineral Oil (Light), NF §	10.0	mL	---	---	

* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.

Preparatory Instruction

IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique

1. **Equipment sterilization:**

Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. THE PHARMACIST IS ADVISED THAT THE SUGGESTED FORMULA IS PRESENTED AT A SPECIFIED STRENGTH AND QUANTITY, AND THAT ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. FURTHER, THE FORMULA SHOULD ONLY BE PROVIDED UPON THE REQUEST AND AUTHORIZATION OF A LICENSED PRESCRIBER. PHARMACISTS USING THIS SUGGESTED FORMULA ARE ADVISED THAT ITS USE AS A MEANS OF THERAPEUTIC INTERVENTION IS BASED ON THE PRESCRIBER'S INDEPENDENT CLINICAL JUDGEMENT AND THE PROFESSIONAL EXPERTISE OF THE PHARMACIST. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE PRECISE STABILITY OF THIS SUGGESTED FORMULA. NO CLAIMS ARE BEING MADE AS TO THE SAFETY OR CLINICAL EFFICACY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. FURTHERMORE, THE NETWORK, TAKES NO RESPONSIBILITY AND MAKES NO RECOMMENDATIONS IN DISPENSING THIS PRODUCT. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.



Suggested Formula	Atropine Sulfate 1% Ophthalmic Ointment (Emulsion, 4 g)	FIN	F 001 769
2.	<p>† <u>Atropine Sulfate 40% Stock Solution preparation:</u></p> <p>A. Incrementally add the Atropine Sulfate (0.100 g) in 0.15 mL of Sterile Water for Injection.</p> <p><u>Specifications:</u> Continuously mix until all solid particles have completely dissolved.</p> <p><u>End result:</u> Homogeneous liquid-like solution.</p> <p>B. Add additional Sterile Water for injection to the mixture (Step 2A) to fill to the required batch size (0.25 mL).</p> <p><u>Specifications:</u> Continuously mix.</p> <p><u>End result:</u> Homogeneous liquid-like solution.</p>		
3.	<p>†† <u>Chlorobutanol 1% Stock Solution preparation:</u></p> <p>A. Combine and mix the following ingredients together:</p> <ul style="list-style-type: none">-Chlorobutanol (Anhydrous) (0.10 g)-Mineral Oil (Light) (10.0 mL) <p><u>Specifications:</u> Continuously mix until all solid particles have completely dissolved.</p> <p><u>End result:</u> Homogeneous liquid-like solution.</p>		
4.	<p><u>Powder-Liquid preparation (Phase A):</u></p> <p>A. Combine and mix the following ingredients together:</p> <ul style="list-style-type: none">- Atropine Sulfate 40% Stock Solution (0.10 mL <i>plus</i> processing error adjustments)- Lanolin (Anhydrous) <p><u>Specifications:</u> Continuously mix.</p> <p><u>End result:</u> Homogeneous paste-like dispersion.</p>		

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. THE PHARMACIST IS ADVISED THAT THE SUGGESTED FORMULA IS PRESENTED AT A SPECIFIED STRENGTH AND QUANTITY, AND THAT ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. FURTHER, THE FORMULA SHOULD ONLY BE PROVIDED UPON THE REQUEST AND AUTHORIZATION OF A LICENSED PRESCRIBER. PHARMACISTS USING THIS SUGGESTED FORMULA ARE ADVISED THAT ITS USE AS A MEANS OF THERAPEUTIC INTERVENTION IS BASED ON THE PRESCRIBER'S INDEPENDENT CLINICAL JUDGEMENT AND THE PROFESSIONAL EXPERTISE OF THE PHARMACIST. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE PRECISE STABILITY OF THIS SUGGESTED FORMULA. NO CLAIMS ARE BEING MADE AS TO THE SAFETY OR CLINICAL EFFICACY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. FURTHERMORE, THE NETWORK, TAKES NO RESPONSIBILITY AND MAKES NO RECOMMENDATIONS IN DISPENSING THIS PRODUCT. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.



Suggested Formula	Atropine Sulfate 1% Ophthalmic Ointment (Emulsion, 4 g)	FIN	F 001 769
5.	<p><u>Powder-Liquid preparation (Phase B):</u></p> <p>A. Combine and mix the following ingredients together:</p> <ul style="list-style-type: none">- Chlorobutanol 1% Stock Solution (1.6 mL <i>plus</i> processing error adjustments)- Petrolatum (White) <p><u>Specifications:</u> Continuously mix.</p> <p><u>End result:</u> Homogeneous paste-like dispersion.</p>		
6.	<p><u>Phase A to Phase B integration:</u></p> <p>A. Incrementally add the homogeneous paste-like dispersion (Step 4A) to the following ingredient:</p> <ul style="list-style-type: none">- Homogeneous paste-like dispersion. (Step 5A) <p><u>Specifications:</u> Continuously mix.</p> <p><u>End result:</u> Homogeneous cream-like dispersion.</p>		
7.	<p><u>Transfer into dispensing container:</u></p> <p>A. Transfer the final product into the recommended dispensing container (see Packaging requirements).</p> <p><u>Note:</u> After sterilization, a sample is to be used as the Test sample for sterility and endotoxin testing.</p>		
8.	<p><u>Sterilization:</u></p> <p>Following the manufacturer's specifications, dry heat sterilize the mixture, then return to ambient temperature.</p> <p><u>Specifications:</u></p> <p>Heating temperature: 150°C Heating time: 60 minutes</p> <p><u>IMPORTANT:</u> The temperature of the heated chamber must reach 150°C before the exposure duration is timed.</p>		

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. THE PHARMACIST IS ADVISED THAT THE SUGGESTED FORMULA IS PRESENTED AT A SPECIFIED STRENGTH AND QUANTITY, AND THAT ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. FURTHER, THE FORMULA SHOULD ONLY BE PROVIDED UPON THE REQUEST AND AUTHORIZATION OF A LICENSED PRESCRIBER. PHARMACISTS USING THIS SUGGESTED FORMULA ARE ADVISED THAT ITS USE AS A MEANS OF THERAPEUTIC INTERVENTION IS BASED ON THE PRESCRIBER'S INDEPENDENT CLINICAL JUDGEMENT AND THE PROFESSIONAL EXPERTISE OF THE PHARMACIST. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE PRECISE STABILITY OF THIS SUGGESTED FORMULA. NO CLAIMS ARE BEING MADE AS TO THE SAFETY OR CLINICAL EFFICACY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. FURTHERMORE, THE NETWORK, TAKES NO RESPONSIBILITY AND MAKES NO RECOMMENDATIONS IN DISPENSING THIS PRODUCT. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.



Suggested Formula	Atropine Sulfate 1% Ophthalmic Ointment (Emulsion, 4 g)	FIN	F 001 769
-------------------	---	-----	-----------

9.	<u>Sterility testing:</u> Validate the Test sample for sterility and endotoxins, in accordance to current USP 797 regulatory guidelines.
----	--

SUGGESTED PRESENTATION

Estimated Beyond-Use Date	14 days BUD based on a successful sterility and endotoxin test result.	Packaging Requirements	Sterile, heat stable, light-resistant ointment tube.	
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.	7	Cap tightly after use.
	2	Keep out of reach of children.	8	May cause blurred vision. Use care when operating a car or machinery.
	3	Keep in a dry place.	9	Protect from light.
	4	For ophthalmic use only.	10	Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.
	5	Do not use if discolored.	11	Do not allow the dropper tip to come into contact with the body or any type of surface in order to prevent contamination.
	6	Keep at room temperature (20°C - 23°C).		
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.			
Patient Instructions	Contact your pharmacist in the event of adverse reactions. IMPORTANT: The quantity of API administered is directly dependent on the quantity of product applied.			

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. THE PHARMACIST IS ADVISED THAT THE SUGGESTED FORMULA IS PRESENTED AT A SPECIFIED STRENGTH AND QUANTITY, AND THAT ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. FURTHER, THE FORMULA SHOULD ONLY BE PROVIDED UPON THE REQUEST AND AUTHORIZATION OF A LICENSED PRESCRIBER. PHARMACISTS USING THIS SUGGESTED FORMULA ARE ADVISED THAT ITS USE AS A MEANS OF THERAPEUTIC INTERVENTION IS BASED ON THE PRESCRIBER'S INDEPENDENT CLINICAL JUDGEMENT AND THE PROFESSIONAL EXPERTISE OF THE PHARMACIST. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE PRECISE STABILITY OF THIS SUGGESTED FORMULA. NO CLAIMS ARE BEING MADE AS TO THE SAFETY OR CLINICAL EFFICACY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. FURTHERMORE, THE NETWORK, TAKES NO RESPONSIBILITY AND MAKES NO RECOMMENDATIONS IN DISPENSING THIS PRODUCT. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.



Suggested Formula	Atropine Sulfate 1% Ophthalmic Ointment (Emulsion, 4 g)	FIN	F 001 769
-------------------	---	-----	-----------

REFERENCES

1.	USP <797> Pharmaceutical Compounding – Sterile Preparations. US Pharmacopeial Convention, Inc. <i>United States Pharmacopeia XXVIII / National Formulary 23</i> . Rockville, MD: 2461.
2.	Ophthalmic, Otic, and Nasal Preparations. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding</i> . American Pharmaceutical Association; 1998: 219.
3.	Lanolin. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 4th Edition</i> . American Pharmaceutical Association; 2003: 333.
4.	Mineral Oil (Light). In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 4th Edition</i> . American Pharmaceutical Association; 2003: 398.
5.	Petrolatum. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 4th Edition</i> . American Pharmaceutical Association; 2003: 419.
6.	Atropine (Monograph). In: O'Neil MJ. <i>The Merck Index 13th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2001: 151.
7.	Atropine. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 3rd Edition</i> . American Pharmaceutical Association; 2005: 34.
8.	Atropine (Monograph). <i>United States Pharmacopeia XXVIII / National Formulary 23</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2004: 200.

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. THE PHARMACIST IS ADVISED THAT THE SUGGESTED FORMULA IS PRESENTED AT A SPECIFIED STRENGTH AND QUANTITY, AND THAT ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. FURTHER, THE FORMULA SHOULD ONLY BE PROVIDED UPON THE REQUEST AND AUTHORIZATION OF A LICENSED PRESCRIBER. PHARMACISTS USING THIS SUGGESTED FORMULA ARE ADVISED THAT ITS USE AS A MEANS OF THERAPEUTIC INTERVENTION IS BASED ON THE PRESCRIBER'S INDEPENDENT CLINICAL JUDGEMENT AND THE PROFESSIONAL EXPERTISE OF THE PHARMACIST. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE PRECISE STABILITY OF THIS SUGGESTED FORMULA. NO CLAIMS ARE BEING MADE AS TO THE SAFETY OR CLINICAL EFFICACY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. FURTHERMORE, THE NETWORK, TAKES NO RESPONSIBILITY AND MAKES NO RECOMMENDATIONS IN DISPENSING THIS PRODUCT. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.